WayPath
Home
The Problem
Our Science
Pipeline
Team
News
Contact Us
WayPath
Home
The Problem
Our Science
Pipeline
Team
News
Contact Us
More
  • Home
  • The Problem
  • Our Science
  • Pipeline
  • Team
  • News
  • Contact Us
  • Home
  • The Problem
  • Our Science
  • Pipeline
  • Team
  • News
  • Contact Us

Groundbreaking Anti-Cancer Regiment For Your Canine

Groundbreaking Anti-Cancer Regiment For Your CanineGroundbreaking Anti-Cancer Regiment For Your CanineGroundbreaking Anti-Cancer Regiment For Your Canine

We're dedicated to your pup's health! Click below to learn why WayPath is different.

Learn More

Groundbreaking Anti-Cancer Regiment For Your Canine

Groundbreaking Anti-Cancer Regiment For Your CanineGroundbreaking Anti-Cancer Regiment For Your CanineGroundbreaking Anti-Cancer Regiment For Your Canine

We're dedicated to your pup's health! Click below to learn why WayPath is different.

Learn More

By The Numbers

300+

2 Patents Granted

2 Patents Granted

Compounds Synthesized

2 Patents Granted

2 Patents Granted

2 Patents Granted

Intellectual property protecting our novel compounds

15,000+

2 Patents Granted

15,000+

New GBM Cases/Year (US)

News and Insights

News and Insights

News and Insights

WayPath Pharma in the News 

Press Release 

Press Release

Announcements

News and Insights

News and Insights

- September 2022 awarded STTR Phase 1 grant from the NIH

- November 2025 Submitted Phase II 

Contact Us

What We Do

Early Days

WayPath's foundational research advanced from compound formulation through pre-clinical testing to a canine pilot study with compelling efficacy data. A pilot study in a canine diagnosed with Hemangiosarcoma (HSA) demonstrated a 26-month life extension following daily oral administration — far exceeding the 2-week median survival expected without treatment.

Commitment to Innovation

WayPath is led by world-class experts in oncology, medicinal chemistry, and drug development. Dr. Krzysztof Reiss co-founded the company following the successful treatment of his own canine companion diagnosed with HSA. A breakthrough that validated the compound's therapeutic potential. Dr. Reiss has authored over 165 peer-reviewed publications spanning cell signaling, energy metabolism, DNA repair, oncogenic viruses, and brain tumor models.

Help in our commitment

WayPath is seeking strategic partners and investors to advance its pipeline through critical milestones:


  • Fund pre-clinical animal trials and secure necessary laboratory infrastructure
  • Complete toxicology studies in canines
  • Conduct large-scale canine clinical trials
  • Submit FDA New Animal Drug Application (NADA)

Subscribe

  • Privacy Policy
  • Terms and Conditions

WayPath

Copyright © 2026 WayPath - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept